United States retail pharmacies now have access to Incruse Ellipta and Arnuity Ellipta, two recently approved GlaxoSmithKline (GSK) products used to treat chronic obstructive pulmonary disease (COPD) and asthma.
"We're excited to share this news with patients," Jorge Bartolome, senior vice president of the GSK Respiratory U.S. Business Unit, said. Forty years after the launch of our first respiratory therapy, we remain committed to innovation and helping a wide range of appropriate patients. These are the third and fourth respiratory products we've introduced since October 2013 in our patented Ellipta inhaler."
Incruse is the first GSK anticholinergic monotherapy, a bronchodilator that improves airflow in the lungs and eases airway smooth muscles. The medication is a long-term maintenance treatment for COPD patients with airflow blockage, including emphysema and chronic bronchitis. Incruse is offered in 62.5mcg of umeclidinium dry inhalation powder and is administered once a day using the Ellipta inhaler.
Arnuity, a once-a-day inhaled corticosteroid, reduces irritation related to asthma and stabilizes asthma symptoms. The medication is the first Ellipta inhaler product for asthma treatment in the United States. Arnuity is available in approved doses of 100 mcg and 200 mcg.
Alerts Sign-up